Today, Paxman publishes the October issue of its newsletter aimed at shareholders, investors and other interested parties.
This month’s issue highlights a clinical study at Montefiore Einstein Cancer Center in New York City (MECC) which will use Paxman Scalp Cooling to investigate if the treatment can help Black and Latina women with textured hair types to mitigate chemotherapy-induced alopecia (CIA). The trial will also determine which women are at a high risk of permanent hair loss as a result of CIA by trying to identify biomarkers for cellular and genetic determinants.
The newsletter also includes information on the release of whitepapers from the successful Scalp Cooing Summit earlier this year, the launch of Paxman’s redesigned company website with pages for local distributors, the latest episode of the Changing the Face of Cancer Podcast on a clinical study at Dana Farber Cancer Institute evaluating scalp cooling for patients with metastatic cancer, the order flow of the month including equipment to Europe, Pakistan, the UK and the US, and supported events and media coverage featuring Paxman during Breast Cancer Awareness Month.
To read the newsletter and subscribe for upcoming issues, follow this link:
Paxman’s investor newsletter is published monthly as a part of the company’s effort to strengthen its market communication together with the IR communication agency Honeybadger. Every published issue of the newsletter is available on Paxman’s website for investors, www.paxman.se. The company encourages feedback and requests on topics for upcoming issues of the newsletter.
